Literature DB >> 23630185

Effect of expectancy and personality on cortical excitability in Parkinson's disease.

Jau-Shin Lou1, Diana M Dimitrova, Richard Hammerschlag, John Nutt, Elizabeth A Hunt, Ryan W Eaton, Sarah C Johnson, Melanie D Davis, Grace C Arnold, Sarah B Andrea, Barry S Oken.   

Abstract

Our previous studies in Parkinson's disease have shown that both levodopa and expectancy of receiving levodopa reduce cortical excitability. We designed this study to evaluate how degree of expectancy and other individual factors modulate placebo response in Parkinson's patients. Twenty-six Parkinson's patients were randomized to 1 of 3 groups: 0%, 50%, and 100% expectancy of receiving levodopa. All subjects received placebo regardless of expectancy group. Subjects completed the NEO-Five Factor Inventory, General Perceived Self-Efficacy Scale, and Perceived Stress Scale. Cortical excitability was measured by the amplitude of motor-evoked potential (MEP) evoked by transcranial magnetic stimulation. Objective physical fatigue of extensor carpi radialis before and after placebo levodopa was also measured. Responders were defined as subjects who responded to the placebo levodopa with a decrease in MEP. Degree of expectancy had a significant effect on MEP response (P < .05). Subjects in the 50% and 100% expectancy groups responded with a decrease in MEP, whereas those in the 0% expectancy group responded with an increase in MEP (P < .05). Responders tended to be more open to experience than nonresponders. There were no significant changes in objective physical fatigue between the expectancy groups or between responders and nonresponders. Expectancy is associated with changes in cortical excitability. Further studies are needed to examine the relationship between personality and placebo effect in Parkinson's patients. © 2013 Movement Disorder Society.
Copyright © 2013 Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; cortical excitability; expectancy; levodopa; transcranial magnetic stimulation (TMS)

Mesh:

Substances:

Year:  2013        PMID: 23630185      PMCID: PMC3735617          DOI: 10.1002/mds.25471

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation.

Authors:  Rodrigo Mercado; Constantine Constantoyannis; Tomasz Mandat; Ajit Kumar; Michael Schulzer; A Jon Stoessl; Christopher R Honey
Journal:  Mov Disord       Date:  2006-09       Impact factor: 10.338

2.  Further evidence for individual differences in placebo responding: an interactionist perspective.

Authors:  Andrew L Geers; Kristin Kosbab; Suzanne G Helfer; Paul E Weiland; Justin A Wellman
Journal:  J Psychosom Res       Date:  2007-05       Impact factor: 3.006

3.  Effects of expectation on placebo-induced dopamine release in Parkinson disease.

Authors:  Sarah C Lidstone; Michael Schulzer; Katherine Dinelle; Edwin Mak; Vesna Sossi; Thomas J Ruth; Raul de la Fuente-Fernández; Anthony G Phillips; A Jon Stoessl
Journal:  Arch Gen Psychiatry       Date:  2010-08

4.  Fatigue in patients with Parkinson's disease.

Authors:  K Karlsen; J P Larsen; E Tandberg; K Jørgensen
Journal:  Mov Disord       Date:  1999-03       Impact factor: 10.338

5.  A global measure of perceived stress.

Authors:  S Cohen; T Kamarck; R Mermelstein
Journal:  J Health Soc Behav       Date:  1983-12

6.  Dopamine release in human ventral striatum and expectation of reward.

Authors:  Raúl de la Fuente-Fernández; Anthony G Phillips; Mariangela Zamburlini; Vesna Sossi; Donald B Calne; Thomas J Ruth; A Jon Stoessl
Journal:  Behav Brain Res       Date:  2002-11-15       Impact factor: 3.332

7.  Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome.

Authors:  Mark J Smith; Linda F Adams; Peter J Schmidt; David R Rubinow; Eric M Wassermann
Journal:  Biol Psychiatry       Date:  2003-10-01       Impact factor: 13.382

8.  Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial.

Authors:  Cynthia McRae; Eva Cherin; T Gayle Yamazaki; Gretchen Diem; Alexander H Vo; Dan Russell; J Heiner Ellgring; Stanley Fahn; Paul Greene; Sandra Dillon; Hal Winfield; Kimberly B Bjugstad; Curt R Freed
Journal:  Arch Gen Psychiatry       Date:  2004-04

9.  Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.

Authors:  Christopher G Goetz; Joanne Wuu; Michael P McDermott; Charles H Adler; Stanley Fahn; Curt R Freed; Robert A Hauser; Warren C Olanow; Ira Shoulson; P K Tandon; Sue Leurgans
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

10.  Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.

Authors:  Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

View more
  2 in total

1.  Motor cortical plasticity in schizophrenia: A meta-analysis of Transcranial Magnetic Stimulation - Electromyography studies.

Authors:  Urvakhsh Meherwan Mehta; Milind Vijay Thanki; Jaya Padmanabhan; Alvaro Pascual-Leone; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2018-11-06       Impact factor: 4.939

Review 2.  Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicine.

Authors:  Katja Weimer; Luana Colloca; Paul Enck
Journal:  Gerontology       Date:  2015       Impact factor: 5.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.